Resolving Inflammation Without Immunosuppression

Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.

Harnessing the Melanocortin System to Resolve Inflammation

SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.


An Oral Selective Melanocortin Agonist

Our lead drug candidate AP1189 is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. AP1189 is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.

BioStock regarding TXP – December 20, 2022

BioStock – November 4, 2022


”During the fourth quarter, we continued the development of AP1189 at a high pace. SynAct’s pipeline was strengthened with the acquisition of TXP Pharma, and our shareholder base was broadened through the private placement. The team at SynAct is grateful for all the support we receive from investors and other stakeholders.”